Trial reportDrug safety2002
Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.
Trial report in Drug safety, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease.Journal of nephrology · 2022Pooled it
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.Blood advances · 2018Guideline
- A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.European journal of clinical pharmacology · 2015Pooled it
- Venous thromboembolic disease.Journal of the National Comprehensive Cancer Network : JNCCN · 2011Guideline
- Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Trial
- CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.BMC cancer · 2013Trial
- Consensus on the Management of the Clinical Challenges of Venous Thromboembolism in Special Situations.Thrombosis and haemostasis · 2025Article
- Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?The pharmacogenomics journal · 2024Review
- Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: a systemic review and meta-analysis.Thrombosis journal · 2024Review
- Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.European journal of clinical pharmacology · 2022Review
- Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020Review
- Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes.PloS one · 2020Article
- Anticoagulation in CKD and ESRD.Journal of nephrology · 2019Review
- Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.Journal of general internal medicine · 2016Article
- Anticoagulation in chronic kidney disease patients-the practical aspects.Clinical kidney journal · 2014Article
- Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.Drugs & aging · 2013Review
- Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?Experimental hematology & oncology · 2013Review
- The antineoplastic effect of low-molecular-weight heparins - a literature review.Contemporary oncology (Poznan, Poland) · 2013Article
- Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Drugs & aging · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesToo few very elderly patients with an age-related renal impairment are included in clinical trials. We conducted a study in order to evaluate the safety profile of tinzaparin, a low molecular weight heparin (LMWH), given at a curative dose (175 IU/kg once daily) in very elderly patients treated for up to 30 days.
settingAn 800-bed geriatric hospital.
designA 1-year prescribing study. PATIENTS: Consecutive in-patients older than age 70, whose creatinine clearance was above 20 ml/min, and requiring full anticoagulation with LMWH were included. MEASUREMENTS: Safety parameters (major bleeding/heparin-induced thrombocytopenia/death) were recorded. Plasma anti-Xa activity levels were regularly measured throughout the treatment period.
resultsTwo-hundred in-patients, mean age 85.2 +/- 6.9 years (70 to 102), mean creatinine clearance 51.2 +/- 22.9 ml/min, were given tinzaparin. Six patients died during the treatment period: only one could be related to the anticoagulation treatment. Three major bleeding episodes (1.5%) were reported. Antithrombotic drug interactions likely contributed to the bleeding event in two of them. Heparin-induced thrombocytopenia was confirmed in two patients (1%). No correlation was found between anti-Xa activity and creatinine clearance or age.
conclusionsTinzaparin can be used safely at a curative dose in very elderly patients as long as (i) the accurate bodyweight-adjusted dose is given; (ii) platelet counts and anti-Xa levels are regularly monitored and; (iii) the interaction with other antithrombotic drugs is correctly managed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.